A broad-acting stimulant that speeds the heart, narrows blood vessels, relaxes the airways, and raises the rate at which the body burns calories. Fat loss is real but small, and largest when paired with caffeine and a firm calorie deficit. Heart rate and blood pressure rise and sleep suffers. Short-horizon metabolic tool; nothing in the evidence speaks to lifespan. (Full Review)

Protocol

Ephedrine with caffeine, the best-evidenced regimen

20 mg + 200 mg caffeine, 3×/day

Alongside a defined energy deficit.

Ephedrine alone

1.5 mg/kg/day

In divided doses; the only dose proven in a placebo-controlled trial of ephedrine without caffeine.

Best time of day

Waking, midday, early afternoon

Split dosing matches the half-life; late dosing is the main driver of insomnia.

Time to effect

Measurable fat loss

4 weeks

Only alongside a defined energy deficit; every positive trial imposed one.

Separation from placebo in weight

8 weeks

From the 24-week trial, where the caffeine combination beat placebo and ephedrine alone did not.

Stimulant and heat-generating effect

1–2 hours

The half-life runs roughly three to six hours, lengthening when urine is alkaline.

Benefits

High: Fat loss during energy restriction; preservation of HDL cholesterol during weight loss; relief of reversible airway narrowing; correction of anesthesia-induced low blood pressure

Medium: Rapid relief of nasal congestion; preservation of lean mass during energy restriction

Low: Increased resting energy expenditure; short-duration exercise performance; muscle function in myasthenic syndromes

Speculative: Appetite suppression; brown fat recruitment

Contraindications

Coronary artery disease, or myocardial infarction within 90 days

Uncontrolled high blood pressure (160/100 mmHg or above)

Atrial fibrillation or any history of significant arrhythmia

Heart failure, New York Heart Association Class III or IV

Prior stroke or transient ischemic attack

Pheochromocytoma

Untreated thyroid overactivity

Closed-angle glaucoma

Benign prostatic hyperplasia with post-void residual volume above 100 mL

Estimated glomerular filtration rate below 30 mL/min/1.73 m²

Pregnancy and lactation

Psychotic disorders, bipolar disorder, or stimulant use disorder

Monoamine oxidase inhibitor use within the preceding 14 days

Competitive athletes under World Anti-Doping Agency rules (urinary ephedrine above 10 µg/mL)

Key Interactions

Caffeine and other stimulants (guarana, synephrine, yohimbine, DMAA)

Non-selective beta-blockers (propranolol, nadolol)

Antidepressants acting on norepinephrine (amitriptyline, venlafaxine, duloxetine, atomoxetine)

Antihypertensive medications (amlodipine, lisinopril, losartan, doxazosin)

Halogenated inhalational anesthetics and digoxin (sevoflurane, desflurane, halothane)

Oxytocic medications (oxytocin, ergometrine)

Thyroid hormone (levothyroxine, liothyronine)

Urinary alkalinisers (sodium bicarbonate, potassium citrate, acetazolamide)

Supplements with additive cardiovascular effects (bitter orange, green tea extract, yohimbine, liquorice root, Rhodiola rosea)

Other interventions (cold exposure protocols, sauna use)

Risk & Side Effects

High: Increased heart rate; increased blood pressure; insomnia, tremor, anxiety, and gastrointestinal upset

Medium: Diminishing response with continued dosing

Low: Serious cardiovascular and cerebrovascular events; psychosis, mania, and escalating misuse; ephedrine-containing kidney stones; heat intolerance during exertion

Speculative: Acute rise in blood glucose, insulin, and thyroid hormones; urinary retention in men with prostate enlargement

Monitoring

Marker	Target	Why
Resting heart rate	50–70 beats/min, seated	Most sensitive marker of stimulant load
Blood pressure (home, seated)	Below 120/80 mmHg	Captures the α-mediated pressure rise
Fasting glucose	75–85 mg/dL (4.2–4.7 mmol/L)	Ephedrine acutely raises circulating glucose
HbA1c	Below 5.3%	Shows whether acute glucose rises translate into worse control
Fasting insulin	Below 5 µIU/mL	Detects the insulin rise seen after dosing
TSH with free T4 and free T3	TSH 0.5–2.0 mIU/L	Ephedrine raises circulating thyroid hormones and thyroid overactivity is a contraindication
Serum potassium	4.0–4.5 mmol/L	β2 stimulation drives potassium into cells
Lipid panel with HDL, LDL, triglycerides	HDL above 60 mg/dL; triglyceride-to-HDL ratio below 2	Ephedrine with caffeine preserved HDL during weight loss; this confirms whether that happens here
Electrocardiogram	No established numeric target; track rhythm, rate, and corrected QT interval against the individual's own baseline	Screens for underlying rhythm disease before exposure
Urine pH	No established target for this purpose; typical values 6.0–7.0	Alkaline urine slows excretion and prolongs exposure; stone risk tracks the other way
Body composition by scan or bioimpedance	No established target; track change from the individual's own baseline — fat mass falling, lean mass held	This is the outcome the intervention is for

Cadence: Home blood pressure and resting heart rate daily for the first two weeks, then weekly; laboratory work at 4 weeks, 12 weeks, and every 3–6 months if dosing continues; body composition at 12 weeks.

Qualitative Assessment

Sleep onset latency and whether sleep feels restorative, not merely whether total hours held
Resting tremor in the hands, especially at the second and third dose of the day
Anxiety, irritability, or a sense of being wired without energy
Appetite, which should fall noticeably within days if the dose is doing anything
Exercise tolerance and perceived exertion at a familiar workload
Palpitations, chest discomfort, or breathlessness, any of which ends the course immediately

Ephedrine for Health & Longevity

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment